ABBV34 trade ideas
$ABBV possible short this week, turning to a long on the bottomNYSE:ABBV looking like a nice potential short coming soon if we reject the top of this wedge. Possible rejection down to the previous resistance turned support flip. Next level of course is the bottom of the wedge.
ABBV daily bullish hammer beginning of wave 3 wave 5 uptrendOrder BUY ABBV NYSE Stop 145.78 LMT 145.78 will be automatically canceled at 20230401 01:00:00 EST
ABBV daily bullish hammer beginning of wave 3 wave 5 uptrend that was ABC correction.
Monthly 3-2-2 reversal Target:200$ Hello dear Traders,
Here is my idea for #ABBV
Price closed above yellow line
Target marked in the chart
Invalidation level marked with red line
IV30 % Rank: 2% Subdued
Good luck!
❤️Please feel free to ask any question in comments. I will try to answer all! Thank you.
Please, support my work with like, thank you!❤️
$ABBV with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $ABBV after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 63.64%.
ABBV bear flag breakABBV has been in a down trend since the start of the year. With a break of the bear flag there is now only the long term trendline to save it.
ABBV Long-term buy confirmedAbbVie Inc. (ABBV) opened today much higher than the 1D MA200 (orange trend-line), which is a strong enough buy signal on its own. Coupled however with the fact that the rebound was achieved on the Higher Lows trend-line that started way back on the COVID (March 23 2020) market bottom, it makes it an even stronger one. In fact on a 2-3 month basis, this is the most optimal buy signal an investor can have.
As you see on this 1D chart, the stock had 4 Higher High touches during that period and the only time the price broke above the Channel Up was on February 16 2022 the break-out of which peaked on April 08 2022. With the help of the Fibonacci Channel levels we can see why the price stopped where it stopped. In fact we also see the important role of the median (Fib 0.5). Based on the above, we expect a new Higher high around the $180.00 price mark.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
ABBV | Loading this Drug Company | LONGAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sell ABBVABBV had a double top on higher time frames, i'd be very cautious. The 2 big support areas i see are $134 and $99.
Technical analysis of AbbVie #ABBVHey traders,
My weekly trade idea.
The daily price is forming a textbook Cup&Handle formation. After the consolidation in the handle phase, the price is ready to go higher. The momentum will push the price and in my opinion, it is headed to test the all-time high in the 180$ area.
The Relative Strength Index broke above its trend line and is moving upward to push the price. Furthermore, when we plot different standard deviations and volume profile, it becomes clear that there is a lot of support and volume right below current price levels!
I would love to hear your thoughts as well.
Cheers
ABBV Textbook Cup&Handle Pattern. Confirmation of uptrend?A textbook example of cup&handle pattern forming on ABBV, I think its interesting to dig deeper into the company, as its a defensive stock for just the conditions at the current moment.
ABBV Bearish Rising WedgeHealthcare has been a safe haven for big institutions, with oil hurting this may be a later breakdown following the market
AbbVie (ABBV) ... Call a Medic please What Happens when Bearish Harmonic Crabs and Cyphers Meet ??
Of all the major 11 S&P sub-sectors, the Health care (XLV) seems the most technically vunerable. (see insert)
Herein we have a well formed Gartley pattern waiting to roll over.
Drilling down to the major holdings of this index, AbbVie Inc. (ABBV) also looks the most vulnerable and ready to roll over,
I see two cypher patterns and one crab terminating. That said, latter is under-formed and I would like to see this crab in waiting terminate in the low $170's to short or exit a long position.
Also the Cypher patterns sometimes turn into Sharks... another eventuality that may happen.
Additionally my momentum indicator in the lower panel needs to decisively roll over.
So we need more pieces in place.
Lots of volatility this week, the Fed, Oil and probably the beginning of holiday constricted trade,
I will advise of a position taken.
Not Investment advice, do your own due diligence and respect overall broad markets and trends,
S.
If ABBV chooses to decline, we are ready.AbbVie - 30d expiry - We look to Sell a break of 132.58 (stop at 137.03)
133 continues to hold back the bears.
132.75 has been pivotal.
Posted a Double Bottom formation.
A break of the recent low at 132.74 should result in a further move lower.
Our profit targets will be 121.01 and 117.01
Resistance: 154 / 157 / 160
Support: 147 / 142 / 137
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ABBV | Bull Flag Formation | LONGNYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie shortAbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutics areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience and also offers treatments for parkinson's, alzheimer's disease.
I guess its stock can be down to $142 and below.
My trade levels
Entry: $158.57
Take profit: $142.54
Stop loss: $164.62
Risk/reward: 2.65
ABBV Inverse Head and Shoulders Bullish - Santa rally Skew Inverse Head And Shoulders with a target of $174.65.
We do see bullish signals momentum wise where 7>21 >200.
Bullish
Let's just hope a bull market does kick in here as we enter the Christmas season with a Santa Rally.
IS $ABBV ready to come up on the right side of its base?Notes:
* Strong up trend on all time frames
* Great earnings track record
* Basing for the past ~8 months
* Now looking to come up on the right side of its base
* Printed a pocket pivot in the last session, indicating institutional buying
* Offering an early entry relative to its 50 day line
Technicals:
Sector: Healthcare - Drug Manufacturers - General
Relative Strength vs. Sector: 6.46
Relative Strength vs. SP500: 2.33
U/D Ratio: 1.4
Base Depth: 28.76%
Distance from breakout buy point: -12.22%
Volume 18.24% above its 15 day avg.
Trade Idea:
* You can enter now as the price is coming off of its 50 day line
* If you're looking for a better entry you can look for one around the ~147 area as that should hold as support moving forward
* If you're looking for a safer entry you can wait for a break and close above the ~152.5 area as that is the immediate resistance coming up
* A daily close below the ~147 area would negate the bullish outlook.
